Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
Sana Biotechnology, Inc. (SANA)
Company Research
Source: GlobeNewswire
SEATTLE, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. “We are thrilled to welcome Dhaval to Sana’s senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipeline, and secure our long-term future,” said Steve Harr, Sana’s President and Chief Executive Officer. “Through decades of experience in research, drug discovery, drug development, and clinical care, Dhaval has successfully led programs in research and early development with substantial contributions to the advancement of 10 FDA-approved treatments. His expertise in immunology and autoimmune diseases make him ideally suited to help advance our clinical pipeline, particularly for B-cell mediated autoimmune diseases and type 1 diabetes, a
Show less
Read more
Impact Snapshot
Event Time:
SANA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SANA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SANA alerts
High impacting Sana Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
SANA
News
- TriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Sana Biotechnology to Present at September 2024 Investor ConferencesGlobeNewswire
- Sana Biotechnology, Inc. (NASDAQ: SANA) had its price target raised by analysts at Citigroup Inc. from $8.00 to $15.00. They now have a "buy" rating on the stock.MarketBeat
- Sana Biotechnology, Inc. (NASDAQ: SANA) had its price target lowered by analysts at HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business UpdatesGlobeNewswire
SANA
Earnings
- 8/8/24 - Miss
SANA
Sec Filings
- 9/12/24 - Form 8-K
- 8/8/24 - Form 10-Q
- 8/8/24 - Form 8-K
- SANA's page on the SEC website